Skip header and navigation

Narrow By

   MORE

2 records – page 1 of 1.

Biomarkers in Inflammatory Bowel Diseases

https://libcat.nshealth.ca/en/permalink/provcat44481
Nik Sheng Ding, Peter De Cruz, editors. --Cham: Springer , c2019.
Available Online
View e-Book
Location
Online
This book provides a comprehensive and complete overview of biomarkers in clinical practice for inflammatory bowel disease (IBD) bringing together the literature in a clear and concise manner. The book bridges the gap between growing knowledge at the bench and current and future applications of biomarkers in clinical practice. The central structure of the book focuses on prognostic and predictive biomarkers in IBD with an emphasis on the fields of research and scientific techniques (genomics, p…
Available Online
View e-Book
Other Authors
Sheng Ding, Nik
De Cruz, Peter
Responsibility
Nik Sheng Ding, Peter De Cruz, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2019
Physical Description
1 online resource (xvii, 365 p.) : 35 illus., 30 illus. in color
ISBN
9783030114466
9783030114459 (Print ed.)
9783030114473 (Print ed.)
Subjects (MeSH)
Biomarkers
Inflammatory Bowel Diseases - diagnosis
Specialty
Clinical Laboratory Techniques
Gastroenterology
Abstract
This book provides a comprehensive and complete overview of biomarkers in clinical practice for inflammatory bowel disease (IBD) bringing together the literature in a clear and concise manner. The book bridges the gap between growing knowledge at the bench and current and future applications of biomarkers in clinical practice. The central structure of the book focuses on prognostic and predictive biomarkers in IBD with an emphasis on the fields of research and scientific techniques (genomics, proteomics and metabonomics) that have led to biomarker discovery and places these biomarkers within a clinical context to help understand their utility in clinical practice. This book will be of use to clinicians who have an interest in using biomarkers in clinical practice as well as clinician researchers and scientists involved in the biomarker research pipeline. The author team comprises experts from around the world in order to bring together the literature in an effort to inform clinicians and researchers about the current state-of-the art in biomarker discovery. It is intended to assist future research efforts and indicate how biomarkers might be best applied to clinical practice both at present and in the future.
Contents
1. Introduction -- Part I. Background to Biomarkers -- 2. Clinical Risk Factors: Lessons from Epidemiology -- 3. Disease Modification in Crohn’s Disease -- 4. Personalized Medicine - Dream or Reality? -- 5. Clinical Trial Design to Facilitate Biomarker Discovery -- Part II. Clinical Algorithms Incorporating Predictive and Prognostic Biomarkers: Crohn’s Disease -- 6. Luminal Crohn’s Disease -- 7. Fibrosis and Stricturing Disease in Crohn’s Disease -- 8. Postoperative Crohn’s Disease -- 9. Perianal Crohn’s Disease -- Part III. Clinical Algorithms Incorporating Predictive and Prognostic Biomarkers: Ulcerative Colitis -- 10. Biomarkers in Acute Severe Ulcerative Colitis -- 11. Chronic Active Ulcerative Colitis -- 12. Refractory Proctitis -- 13. UC Surveillance -- 14. The Role of Biomarkers in the Ileal Anal Pouch -- Part IV. Clinical Algorithms Incorporating Predictive and Prognostic Biomarkers: Specialised Scenarios -- 15. Extra-intestinal Manifestations in Inflammatory Bowel Disease: Diagnosis and Management -- 16. Primary Sclerosing Cholangitis Overlapping with IBD -- 17. Pregnancy and IBD -- 18. Nutrition in IBD -- 19. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Thiopurines -- 20. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Biologics -- 21. Drug Toxicity: Personalising IBD Therapeutics–The Use of Genetic Biomarkers to Reduce Drug Toxicity -- 22. Biomarkers for Remote Monitoring -- Part V. Scientific Platforms for Biomarker Discovery -- 23. Exposome and Diet -- 24. The Microbiome in IBD -- 25. Metabolic Profiling in IBD -- 26. Innate and Adaptive Immunology -- 27. Genetic and Genomic Markers for Prognostication -- 28. Risk Alleles for Drug Targets: Genomic Markers of Drug Response -- Part VI. Conclusion -- 29. Big Data Meets Real World! The Use of Clinical Informatics in Biomarker Research -- 30. Bringing It Altogether: A Systems Biology Approach to Biomarkers in Inflammatory Bowel Disease.
Format
e-Book
Location
Online
Less detail

Treatment of Inflammatory Bowel Disease with Biologics

https://libcat.nshealth.ca/en/permalink/provcat42935
edited by Adam S. Cheifetz, Joseph D. Feuerstein. --Cham, Switzerland: Springer , c2018.
Available Online
View e-Book
Location
Online
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment …
Available Online
View e-Book
Other Authors
Cheifetz, Adam S.
Feuerstein, Joseph D.
Responsibility
edited by Adam S. Cheifetz, Joseph D. Feuerstein
Place of Publication
Cham, Switzerland
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xi, 335 p.) : 22 illus., 19 illus. in color
ISBN
9783319602769
9783319602752 (print ed.)
9783319602776 (print ed.)
9783319868233 (print ed.)
Subjects (MeSH)
Anti-Inflammatory Agents - therapeutic use
Biological Products - therapeutic use
Inflammatory Bowel Diseases - drug therapy
Specialty
Biological Therapy
Gastroenterology
Abstract
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.
Contents
Mechanism of Action and Pharmacokinetics of Biologics -- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis -- Anti-tumor Necrosis Factor Agents in Crohn's Disease -- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease -- Use of Biologics in the Postoperative Management of Crohn's Disease -- Biologics in Pregnancy and Breastfeeding -- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease -- Therapeutic Drug Monitoring of Biologic Agents -- Use of Biologics in Crohn's Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks -- Cessation of Biologics—Can it be Done? -- Biologic Therapy in Pediatric Inflammatory Bowel Disease -- Infectious Complications of Biologics -- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy -- Non-infectious and Non-malignant Complications of Biologics -- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances -- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications -- Novel Agents in Inflammatory Bowel Disease -- Quality, Safety, and Practical Considerations of Using Biologic Therapies.
Format
e-Book
Location
Online
Less detail